ADC Therapeutics plunges after patient deaths in blood cancer drug trial

ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among ​treated patients, despite meeting its main goal of improving progression-free survival.